Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages
- 1 August 2001
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 82 (2) , 323-328
- https://doi.org/10.1006/gyno.2001.6272
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicinCancer, 2001
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.International Journal of Oncology, 1999
- Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patientsAnnals of Oncology, 1997
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996